雷帕霉素靶蛋白抑制剂在移植后新发肿瘤中的应用

Mammalian target of rapamycin inhibitors in the treatment of malignancy after organ transplantation

随着外科技术的改进和新免疫抑制剂的应用,器官移植的存活率已明显提高,但恶性肿瘤仍是影响移植物长期存活的主要因素之一。以西罗莫司为代表的哺乳动物雷帕霉素靶蛋白(mTOR)抑制剂除了具有强有力的免疫抑制作用外,其对恶性肿瘤的靶向治疗作用近年逐步得到确认,并在临床得到推广。本文探讨该类药物在器官移植后新发肿瘤中的应用,包括其作用机理、临床疗效和不良反应,以期为临床移植后肿瘤的治疗提供新的途径。

As the improvement of surgical technique and the introduction of powerful immunosuppressors,the graft survival rates have increased greatly.Malignancy has been one of the important factors affecting the long graft survival.Those mammalian target of rapamycin(mTOR)inhibitors such as sirolimus have both immunosuppressive effects on the grafts and targeted anti-tumor effects on the malignancies.Here we reviewed the mechanism,clinical outcome and the adverse reactions of these mTOR inhibitors in the treatment o...